摘要
目的 通过对Graves病患者服用碳酸锂后甲状腺摄131I率变化的观察,探讨碳酸锂在低摄131I率Graves病患者131I治疗中的应用价值.方法 46例摄131I率低的Graves病患者口服碳酸锂,每日3次,每次250 mg,餐后服用,连续服用10 d,分别在用药前、后进行甲状腺摄131I率的测定,并比较用药前后差别.结果 46例摄131I率低的Graves病患者在服用碳酸锂10 d后甲状腺的24 h摄131I率比服用前明显升高（27%）,两者具有统计学差异（t=3.24,P＜0.01）.结论 碳酸锂能够提高Graves病患者的甲状腺摄131I率,达到了患者要求并减少了131I的治疗用量,具有实用推广价值.
Objective To observe 131I uptake rate of Graves＇s patients after taking lithium carbonate thyroid and to investigate application value of lithium carbonate for the low 131I uptake rate in Graves＇s patients. Methods Forty-six low 131I uptake Graves＇s patients take lithium carbonate orally after meal, three times daily, 250 mg each time, and served 10 days, detected 131I uptake rate respectively before and after lithium carbonate treatment and compared the changes. Result Low 131I uptake rate after intake of lithium carbonate with 10 days was significantly higher （27%） in 24 hours than before with a statistic difference （t=3.24, P〈0.01）. Conclusions Lithium carbonate can improved the intake of thyroid 131I Graves＇s patients, met the requirements of patients and reduced the amount of 131I treatment. So it was valuable for clinical application.
出处
《国际放射医学核医学杂志》
2010年第2期100-101,共2页
International Journal of Radiation Medicine and Nuclear Medicine
